NCCN Guidelines for Patients
Waldenström’s Macroglobulinemia, Version 1.2017
Part 4 describes treatment options for
people with WM. Patients with WM
who have symptoms receive treatment.
Options for primary treatment are listed in
Guide 4. Guide 5 describes the response
to primary treatment. Guide 6 lists next
steps based on the response. Guide 7
lists further treatment for WM.
This information is taken from the treatment
guidelines written by NCCN experts of WM. These
treatment guidelines list options for people with WM
in general. Thus, your doctors may suggest other
treatment for you based on your health and personal
needs. Discuss and decide on your treatment plan
with your doctor.
Your doctor may begin with plasmapheresis. You can
get this treatment before systemic therapy is given.
Plasmapheresis is done to reduce IgM in the blood
that causes hyperviscosity and its symptoms. This
type of treatment can prepare your body for the next
treatment in line. These options include drugs that
are non-stem cell toxic treatment. These drugs will
not limit your options for future treatment such as a
stem cell transplant.
A stem cell transplant may be an option for a small
number of people with WM, especially people with
complications of amyloid or who have had multiple
relapses. For example, a younger person may have
a stem cell transplant in the future. If this is the case,
he or she will likely not get certain drugs that can
cause damage to normal blood cells, especially if
given often. Such damage to cells could possibly
lead to other types of serious blood problems, un-
related to WM, such as myelodysplasia and even